How can immunology contribute to the control of tuberculosis?
about
Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteriaSecretion of interleukin-8 by human-derived cell lines infected with Mycobacterium bovisDC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosisMycobacterium tuberculosis: success through dormancyStriking the Right Balance Determines TB or Not TBInnovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide AnalysesIdentification and Characterization of Lipase Activity and Immunogenicity of LipL from Mycobacterium tuberculosisCrystal Structure of Mycobacterium tuberculosis Zinc-dependent Metalloprotease-1 (Zmp1), a Metalloprotease Involved in PathogenicityExperimental Models of Foamy Macrophages and Approaches for Dissecting the Mechanisms of Lipid Accumulation and Consumption during Dormancy and Reactivation of TuberculosisAnnulling a dangerous liaison: vaccination strategies against AIDS and tuberculosisSuppression of the NF-κB pathway by diesel exhaust particles impairs human antimycobacterial immunityIs adipose tissue a place for Mycobacterium tuberculosis persistence?The Mycobacterium tuberculosis ORF Rv0654 encodes a carotenoid oxygenase mediating central and excentric cleavage of conventional and aromatic carotenoidsA member of the cAMP receptor protein family of transcription regulators in Mycobacterium tuberculosis is required for virulence in mice and controls transcription of the rpfA gene coding for a resuscitation promoting factorA monoacylglycerol lipase from Mycobacterium smegmatis Involved in bacterial cell interactionMycobacterial lipoarabinomannan mediates physical interactions between TLR1 and TLR2 to induce signalingDevelopment of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccinationCompounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).The scavenger protein apoptosis inhibitor of macrophages (AIM) potentiates the antimicrobial response against Mycobacterium tuberculosis by enhancing autophagy.Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analysesCritical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation.T-cell and serological responses to Erp, an exported Mycobacterium tuberculosis protein, in tuberculosis patients and healthy individuals.Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosisIdentification and characterization of two novel methyltransferase genes that determine the serotype 12-specific structure of glycopeptidolipids of Mycobacterium intracellulareSafety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AInfection with Helicobacter pylori is associated with protection against tuberculosis.Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activityImmune regulation of a chronic bacteria infection and consequences for pathogen transmission.Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant miceRecombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages.The immunology of tuberculosis: from bench to bedside.Cytomegalovirus infection- and age-dependent changes in human CD8+ T-cell cytokine expression patternsIdentification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis ImmunoproteomeOptimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85BAnamnestic responses of mice following Mycobacterium tuberculosis infection.Concomitant patterns of tuberculosis and sarcoidosis.Improved tuberculosis DNA vaccines by formulation in cationic lipids.Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
P2860
Q22241488-C8BF91CC-02B1-4FDC-A471-83A4149E1340Q24633691-1E1B3804-F7E7-4244-865F-9EEDC8418BC9Q24683212-08AEA84C-DB34-4F81-B068-11941BD23F4CQ24816920-7F95B863-3BC1-4D24-9F15-1B1BD5F6E768Q26852023-CADF73ED-9350-4367-9FE4-F19713DFBE58Q27001010-624E344B-2DA2-4B38-856F-2E7055B9734FQ27027110-227FDD9C-17DB-4C05-B78D-BDBB4CEADBB2Q27317390-A1E1F815-B537-4138-9DC4-C4F066EFB706Q27671497-828CF3CE-907B-46FC-9F54-FB8EFE5D7517Q28067031-8A059924-CE21-4269-A32B-959274B4A16AQ28243702-ECDB40CC-3EEB-4196-9A92-39AC0B1A5EFEQ28397253-6DB22880-BA94-4F26-B6CF-8D0700CF4DF2Q28469097-75C16EB2-E851-468D-811C-0D529869716AQ28486839-78188BCA-BFCD-43CA-8AFA-08463E609568Q28487026-0E14131E-EF60-4D4D-B853-AF099B114E05Q28501842-1FE0ABFF-B010-4756-BAD9-ABEAD9E194D5Q29030022-1D885550-A19F-487A-AAFE-79D6C0636388Q30231394-0F495A53-A0B0-4BEC-9332-BC9BE1E0F2E9Q30907456-81555396-6FB6-4C14-BB8F-890F3038717BQ31143734-48428748-A87F-4C0B-96C7-DB53E8F3DC1AQ31156691-81390E8F-C73E-427D-B519-742C3A223868Q33267290-D6F9F885-4CD8-46ED-B0B3-CD3678E7EA9FQ33291869-FFA26F7E-7673-4AC0-80EE-7013DA9ABF90Q33294711-D2DE1EFE-7016-4142-98A4-633CD8E6C3CDQ33306297-C72B0EA5-13F0-4D8E-BECF-E820113B2F84Q33468451-12D8345A-93B9-4FA1-8222-2B0D6AAC394AQ33526339-7E23993E-627B-4450-BA11-916AE2FC89BEQ33535876-397BFEA7-585A-4523-AC2C-287AD2CA46C6Q33672341-05CB5760-7F70-483E-AB8F-4D8D4C05C909Q33715964-F8EAAFE7-D422-495D-8A53-BBD01561F5C2Q33716100-FE9EF22D-5509-4E4D-8D31-55E035D334A8Q33777367-C18FFEA9-5D87-41D6-ADD0-F9AE67AD189DQ33909200-19A81080-F47F-4D10-B855-89DA74F6DC09Q33970528-8017A13E-F73A-4E3B-B0A8-6D092620B85DQ34024201-FF69D74B-CE29-4488-91D4-78D226F24669Q34033825-8FA62A53-B78C-4C12-9452-5F4A4F9BE515Q34034280-F6766035-88F3-4E31-ABB6-D083CA409864Q34126904-E0DCFBA5-F93F-4920-8D93-3AB0DD636EEFQ34126930-8C5091EB-903F-4AA9-BDEA-9E43633114ABQ34193844-DF30370B-AB0C-4CA3-BAE2-045DCD9AC84C
P2860
How can immunology contribute to the control of tuberculosis?
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
How can immunology contribute to the control of tuberculosis?
@ast
How can immunology contribute to the control of tuberculosis?
@en
How can immunology contribute to the control of tuberculosis?
@nl
type
label
How can immunology contribute to the control of tuberculosis?
@ast
How can immunology contribute to the control of tuberculosis?
@en
How can immunology contribute to the control of tuberculosis?
@nl
prefLabel
How can immunology contribute to the control of tuberculosis?
@ast
How can immunology contribute to the control of tuberculosis?
@en
How can immunology contribute to the control of tuberculosis?
@nl
P356
P1476
How can immunology contribute to the control of tuberculosis?
@en
P2093
Kaufmann SH
P356
10.1038/35095558
P577
2001-10-01T00:00:00Z